Malignant peripheral nerve sheath tumour: the decisions you may face
3 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Localised
Wide resection with preoperative or postoperative radiotherapy; nerve sacrifice and reconstruction as needed; consider neoadjuvant or adjuvant anthracycline-ifosfamide for large high-grade tumours.
Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.
- Preserves function without compromising survival
- Custom implants for pelvis and spine
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
- Conformal dose, fewer side effects
- Hypofractionation saves visits
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Implant infection and mechanical failure over decades
- Requires specialist sarcoma centres
- Low-dose bath to normal tissue
- Motion management
- Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
- Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.
- Between Limb-salvage surgery and endoprosthetic reconstruction, IMRT / IGRT (modern external beam), Doxorubicin and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (localised), which of the standard options do you recommend and why?Why: Guideline options include: Wide resection with preoperative or postoperative radiotherapy; nerve sacrifice and reconstruction as needed; consider neoadjuvant or adjuvant anthracycline-ifosfamide for large high-grade tumours.
- Am I a candidate for Doxorubicin, Ifosfamide, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.
Advanced
Doxorubicin plus ifosfamide (EORTC 62012), then ifosfamide-etoposide or trials; response rates lower in NF1-associated tumours.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
Etoposide is a chemotherapy from the mayapple plant, essential to curing testicular cancer (BEP), treating small-cell lung cancer, lymphomas, childhood sarcomas and leukaemias, and used in transplant conditioning.
- Tests Doxorubicin, IfosfamideAdvanced soft tissue sarcoma, first line: doxorubicin plus ifosfamide versus doxorubicin alone
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Median OS 14.3 vs 12.8 months (HR 0.83, not significant); median PFS 7.4 vs 4.6 months (HR 0.74).
Overall survival (median) (months): Doxorubicin + ifosfamide 14.3 vs Doxorubicin 12.8 · HR 0.83 · source
- Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
- Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.
- Reduce to 75% for CrCl 15-50.
- Between Doxorubicin, Ifosfamide and Etoposide, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in EORTC 62012, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (advanced), which of the standard options do you recommend and why?Why: Guideline options include: Doxorubicin plus ifosfamide (EORTC 62012), then ifosfamide-etoposide or trials; response rates lower in NF1-associated tumours.
- Am I a candidate for Doxorubicin, Ifosfamide, Etoposide, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EORTC 62012 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Neurofibromatosis type 1 surveillance
Whole-body MRI and FDG-PET for growing or painful plexiform neurofibromas; biopsy of atypical lesions; MEK inhibitors for symptomatic plexiform neurofibromas.
MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.
- No ionising radiation
- Best soft-tissue and brain imaging
- Functional sequences (diffusion, perfusion)
PET and CT in one machine, so hot spots on the PET are pinned to exact locations on the CT.
- Anatomy plus biology
- Standard for lymphoma, lung, melanoma, head and neck staging
Selumetinib (Koselugo) is the first medicine for children and adults with neurofibromatosis type 1 whose plexiform neurofibromas, benign but disfiguring and painful nerve tumours, cannot be removed by surgery.
Mirdametinib (Gomekli in the US, Ezmekly in Europe) is a MEK-blocking capsule or dispersible tablet for adults and children with neurofibromatosis type 1 whose plexiform neurofibromas cannot be removed surgically; it is the first such drug approved for adults.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Between MRI, PET/CT, Selumetinib and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (neurofibromatosis type 1 surveillance), which of the standard options do you recommend and why?Why: Guideline options include: Whole-body MRI and FDG-PET for growing or painful plexiform neurofibromas; biopsy of atypical lesions; MEK inhibitors for symptomatic plexiform neurofibromas.
- Am I a candidate for Selumetinib, Mirdametinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.